Invention patent of IMM0306 was authorized by the US Patent Office
On March 29, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") declared that the bispecific antibody drug targeting both CD47 and CD20 (Project No.: IMM0306) was authorized by the US Patent Office (APPLICATION No.: US16/489,360). So far, the IMM0306 project has been granted patents in China, the United States and Japan, consolidating ImmuneOnco's leading position in CD47 target drug development and bispecific antibody research.
IMM0306 was authorized by the China National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA) on December 28, 2020 and January 9, 2021 respectively to conduct clinical trials. On September 15th and March 9th, 2022, the invention patent was authorized by the China Intellectual Property Office (China Patent Application No.: CN201710151979.6) and the Japanese Patent Office (Japanese Patent Application No.: JP2019 - 542396).
Founder, Chairman and CEO of the Company, Dr. Tian Wenzhi said:
"We are very pleased to know that our IMM0306 invention patent has been authorized by the US Patent Office. IMM0306 is an antibody-receptor recombinant protein (mAb-Trap) that targets both CD47 and CD20, and is the first CD47xCD20 bispecific molecule to enter clinical trials globally. IMM0306 does not bind to human red blood cells, the efficacy of the same dose is significantly better than that of Rituximab and it is hopeful that it will surpass Rituximab in the future as alternative first line treatment choice for patients with B-cell lymphoma. At present, the clinical phase I trial research conducted in China progresses rapidly, and the preliminary safety and efficacy data is encouraging. Clinical trials in the United States have also started, and we feel confident to the future of IMM0306.”
"We will continue to further expand clinical trial research of imm0306 to speed up the launch of IMM0306 to the market so as to benefit cancer patients."
IMM0306 is an antibody receptor recombinant protein (mAb-Trap) targeting CD47 and CD20 at the same time. It is the first in class in the world. It is a bispecific antibody drug candidate with independent intellectual property rights of ImmuneOnco. It can act on tumor targets and regulate immune system at the same time, and exert strong anti-tumor effect by activating macrophages and NK cells.